674,250 Sarepta Therapeutics, Inc. $SRPT Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4,355.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 689,732 shares of the biotechnology company’s stock after acquiring an additional 674,250 shares during the period. Pictet Asset Management Holding SA owned 0.65% of Sarepta Therapeutics worth $12,567,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in SRPT. Meeder Asset Management Inc. purchased a new stake in Sarepta Therapeutics in the second quarter worth $27,000. Pinnacle Wealth Planning Services Inc. grew its holdings in Sarepta Therapeutics by 50.6% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 598 shares during the period. Nykredit A S bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $43,000. Ancora Advisors LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $45,000. Finally, Allworth Financial LP bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $58,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $16.01 on Friday. The business has a 50-day simple moving average of $18.73 and a two-hundred day simple moving average of $18.54. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -11.69, a PEG ratio of 0.39 and a beta of 0.45. Sarepta Therapeutics, Inc. has a 52 week low of $14.68 and a 52 week high of $24.68. The company has a quick ratio of 2.13, a current ratio of 3.46 and a debt-to-equity ratio of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $381.35 million during the quarter, compared to analysts’ expectations of $352.20 million. Sarepta Therapeutics had a negative net margin of 5.86% and a negative return on equity of 0.20%. The company’s revenue for the quarter was down 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.13) earnings per share. On average, analysts expect that Sarepta Therapeutics, Inc. will post 3.27 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Benchmark reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, September 9th. Zacks Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Finally, William Blair raised Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and an average price target of $23.67.

About Sarepta Therapeutics

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.